Abstract

Although endogenous cardiac repair by recruitment of stem cells may serve as a therapeutic approach to healing a damaged heart, how to effectively enhance the migration of stem cells to the damaged heart is unclear. Here, we examined whether the combined administration of prostacyclin agonist (ONO1301), a multiple-cytokine inducer, and stem cell niche laminin-221 (LM221), enhances regeneration through endogenous cardiac repair. We administered ONO1301- and LM221-immersed sheets, LM221-immersed sheets, ONO1301-immersed sheets, and PBS-immersed sheets (control) to an acute infarction rat model. Four weeks later, cardiac function, histology, and cytokine expression were analysed. The combined administration of LM221 and ONO1301 upregulated angiogenic and chemotactic factors in the myocardium after 4 weeks and enhanced the accumulation of ILB4 positive cells, SMA positive cells, and platelet-derived growth factor receptor alpha (PDGFRα) and CD90 double-positive cells, leading to the generation of mature microvascular networks. Interstitial fibrosis reduced and functional recovery was prominent in LM221- and ONO1301-administrated hearts as compared with those in ONO1301-administrated or control hearts. LM221 and ONO1301 combination enhanced recruitment of PDGFRα and CD90 double-positive cells, maturation of vessels, and functional recovery in rat acute myocardial infarction hearts, highlighting a new promising acellular approach for the failed heart.

Highlights

  • Endogenous cardiac repair by recruitment of stem cells may serve as a therapeutic approach to healing a damaged heart, how to effectively enhance the migration of stem cells to the damaged heart is unclear

  • Combined administration of LM221 and ONO1301 in acute myocardial infarction (AMI) model hearts led to increased gene expression of angiogenic factors such as hepatocyte growth factor (HGF), placental growth factor (PlGF), angiopoietin 1 (Ang1), fibroblast growth factor 2 (FGF2), Tie[2], and platelet-derived growth factor beta (PDGF-B)

  • The relative expression of HGF was remarkably enhanced in LM221- and ONO1301-administrated hearts compared to control hearts and LM221-administrated hearts (Control hearts; 1.00 ± 0.02, LM221-administrated hearts; 1.81 ± 0.04, LM221- and ONO1301-administrated hearts; 3.30 ± 0.23, p < 0.05), there was no significant difference between LM221- and ONO1301-administrated hearts and ONO1301-administrated hearts

Read more

Summary

Introduction

Endogenous cardiac repair by recruitment of stem cells may serve as a therapeutic approach to healing a damaged heart, how to effectively enhance the migration of stem cells to the damaged heart is unclear. We examined whether the combined administration of prostacyclin agonist (ONO1301), a multiple-cytokine inducer, and stem cell niche laminin-221 (LM221), enhances regeneration through endogenous cardiac repair. LM221 and ONO1301 combination enhanced recruitment of PDGFRα and CD90 double-positive cells, maturation of vessels, and functional recovery in rat acute myocardial infarction hearts, highlighting a new promising acellular approach for the failed heart. Our laboratory demonstrated that administration of ONO1301 for acute and chronic ischemic cardiac failure animal models yielded proangiogenic cytokines, such as vascular endothelial growth factor (VEGF) or hepatocyte growth factor (HGF), and stromal cell-derived factor-1 (SDF-1), contributing to the repair of the tissues and inducing functional r­ ecovery[3,4,5,6]

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.